--- title: "Weekly Recap | AKESO -0.28%, new drug progress fuels swings" type: "News" locale: "en" url: "https://longbridge.com/en/news/296666794.md" description: "AKESO (9926.HK) edged 0.28% lower over the four trading days this week, closing at HK$90.25, underperforming the Hang Seng Index’s 2.19% rally by roughly 2.47 percentage points. It was a volatile week, with a 13.18% intra-week swing. The price action traced a sharp ‘V’ shape: an early sell-off on Monday pushed the stock to a low of HK$87.65, before sentiment reversed mid-week and drove a rally that peaked at HK$99.45 on Wednesday." datetime: "2026-08-22T04:29:34.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/296666794.md) - [en](https://longbridge.com/en/news/296666794.md) - [zh-HK](https://longbridge.com/zh-HK/news/296666794.md) generator: "portal-rs" --- # Weekly Recap | AKESO -0.28%, new drug progress fuels swings ## The Week AKESO (9926.HK) edged 0.28% lower over the four trading days this week, closing at HK$90.25, underperforming the Hang Seng Index’s 2.19% rally by roughly 2.47 percentage points. It was a volatile week, with a 13.18% intra-week swing. The price action traced a sharp ‘V’ shape: an early sell-off on Monday pushed the stock to a low of HK$87.65, before sentiment reversed mid-week and drove a rally that peaked at HK$99.45 on Wednesday. The advance proved unsustainable, however, with the stock retreating back to the HK$90 level by Thursday. Average daily volume reached 15.2m shares, about 26% above the 60-day median, indicating elevated trading interest. ## Key Events AKESO’s price swings this week were closely tied to its development pipeline. A sharp 7% drop on Monday was followed by a series of positive fundamental updates. Mid-week, the company’s subsidiary Aikobio secured IND clearance from China’s NMPA for its flu-prevention drug AK0406. The strongest catalyst came on Thursday, when news of a new indication approval for AKESO itself sent shares surging over 10% intraday, lifting the broader Hong Kong biotech sector. Near the end of the week, the company announced that the NMPA had accepted a Phase I trial application for AK157D1, a B7-H3 ADC targeting solid tumours. Additionally, the company confirmed on Monday that its board meeting will take place on 27 August to approve the interim results for the 2026 fiscal year. ## Analyst Ratings AKESO is covered by 24 analysts, with a consensus rating of ‘Strong Buy’. The breakdown shows 18 ‘Buy’ ratings, 5 ‘Overweight’, and 1 ‘Hold’ — no analysts rate the stock ‘Underweight’ or ‘Sell’. Within the biotechnology sector, AKESO ranks second out of 51 covered companies. The consensus target price sits at HK$167.82, implying an 86% upside from the current share price. However, the range of individual targets is fairly wide, spanning from a low of HK$129.64 to a high of HK$227.07, reflecting a notable dispersion in long-term value estimates. ## The Week Ahead The key event on the horizon is AKESO’s 2026 interim results, due on Thursday, 27 August. The market expects revenue of roughly HK$2.75 billion. This report will serve as a crucial test of the company’s commercial execution and the value of its pipeline, with investors likely to focus on core product sales momentum, R&D efficiency, and any forward-looking milestones flagged by management. ## In Short AKESO closed a volatile week nearly flat, caught between a stream of positive pipeline catalysts and pockets of selling pressure. The regulatory progress on multiple fronts and the overwhelmingly positive analyst consensus signal strong conviction in the company’s long-term story. Yet the failure to hold gains near the HK$100 level shows that the market is demanding more proof. The upcoming interim results will be the next critical checkpoint for whether the current share price can be sustained. *This article is generated by LongbridgeAI from market data, for information only and not investment advice.* ### Related Stocks - [09926.HK](https://longbridge.com/en/quote/09926.HK.md) ## Related News & Research - [Akeso says Phase III ivonescimab-chemo trial in biliary tract cancer meets overall survival endpoint](https://longbridge.com/en/news/297257007.md) - [AKESO Ivonescimab Plus Chemotherapy Phase III Study Meets Primary Overall Survival Endpoint](https://longbridge.com/en/news/296969973.md) - [China’s Akeso says cancer drug beat AstraZeneca’s Imfinzi in phase 3 trial](https://longbridge.com/en/news/297148879.md) - [Akeso says China NMPA clears Phase I trial for B7-H3 ADC AK157D1 in solid tumors](https://longbridge.com/en/news/296571352.md) - [CMBI Cuts AKESO TP to HKD138.42; Ivonescimab Data Readout in 2H Seen as Catalyst](https://longbridge.com/en/news/297595073.md) --- > **Disclaimer: This article is for reference only and does not constitute any investment advice.**